A Novel Application of Ketamine for Improving Perioperative Sleep Disturbances

Bijia Song, Junchao Zhu, Bijia Song, Junchao Zhu

Abstract

Perioperative sleep disturbances are commonly observed before, during, and after surgery and can be caused by several factors, such as preoperative negative moods, general anesthetics, surgery trauma, and pain. Over the past decade, the fast-acting antidepressant effects of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine represent one of the most attractive discoveries in the field of psychiatry, such as antidepressant and anxiolytic effects. It is also widely used as a short-acting anesthetic and analgesic. Recent research has revealed new possible applications for ketamine, such as for perioperative sleep disorders and circadian rhythm disorders. Here, we summarize the risk factors for perioperative sleep disturbances, outcomes of perioperative sleep disturbances, and mechanism of action of ketamine in improving perioperative sleep quality.

Keywords: anti-inflammation; antidepressant; anxiolytic; ketamine; perioperative sleep disturbances.

Conflict of interest statement

The authors declare no competing interests in this work.

© 2021 Song and Zhu.

Figures

Figure 1
Figure 1
Antidepressant mechanisms of ketamine and potential biochemical biomarkers.
Figure 2
Figure 2
Analgesia and anti-inflammation mechanism of ketamine.
Figure 3
Figure 3
Regulation mechanism of ketamine on sleep and circadian system.

References

    1. Cok OY, Seet E, Kumar CM, Joshi GP. Perioperative considerations and anesthesia management in patients with obstructive sleep apnea undergoing ophthalmic surgery. J Cataract Refract Surg. 2019;45:1026–1031. doi:10.1016/j.jcrs.2019.02.044
    1. Rhon DI, Snodgrass SJ, Cleland JA, Cook CE. Comorbid insomnia and sleep apnea are associated with greater downstream health care utilization and chronic opioid use after arthroscopic hip surgery. Pain Physician. 2019;22:E351–60. doi:10.36076/ppj/2019.22.E351
    1. Chouchou F, Khoury S, Chauny JM, Denis R, Lavigne GJ. Postoperative sleep disruptions: a potential catalyst of acute pain? Sleep Med Rev. 2014;18:273–282. doi:10.1016/j.smrv.2013.07.002
    1. Ruyi Z. Relationship between sleep condition and negative psychology in perioperative patients. Chin J Practical Neurodiseases. 2014;17(17):93.
    1. Trbojević-Stanković J, Stojimirović B, Bukumirić Z, et al. Depression and quality of sleep in maintenance hemodialysis patients. Srp Arh Celok Lek. 2014;142(7–8):437–443. doi:10.2298/SARH1408437T
    1. Mansano-Schlosser TC, Ceolim MF. Factors associated with poor sleep quality in women with cancer. Rev Lat Am Enfermagem. 2017;25:e2858. doi:10.1590/1518-8345.1478.2858
    1. Nie A, Wang C, Song Y, Xie X, Yang H, Chen H. Prevalence and factors associated with disturbed sleep in outpatients with ankylosing spondylitis. Clin Rheumatol. 2018;37(8):2161–2168. doi:10.1007/s10067-018-4190-3
    1. Herrero Babiloni A, De Koninck BP, Beetz G, De Beaumont L, Martel MO, Lavigne GJ. Sleep and pain: recent insights, mechanisms, and future directions in the investigation of this relationship. J Neural Transm. 2020;127(4):647–660. doi:10.1007/s00702-019-02067-z
    1. Tamisier R, Fabre F, O’Donoghue F, Lévy P, Payen JF, Pépin JL. Anesthesia and sleep apnea. Sleep Med Rev. 2018;40:79–92. doi:10.1016/j.smrv.2017.10.006
    1. Yaremchuk K. Sleep Disorders in the Elderly. Clin Geriatr Med. 2018;34(2):205–216. doi:10.1016/j.cger.2018.01.008
    1. Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep Apnea: types, Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol. 2017;69(7):841–858. doi:10.1016/j.jacc.2016.11.069
    1. de Almondes KM, Costa MV, Malloy-Diniz LF, Diniz BS. The relationship between sleep complaints, depression, and executive functions on older adults. Front Psychol. 2016;7:1–8. doi:10.3389/fpsyg.2016.01547
    1. Kaur U, Pathak BK, Singh A, Chakrabarti SS. Esketamine: a glimmer of hope in treatment-resistant depression. Eur Arch Psychiatry Clin Neurosci. 2021;271(3):417–429. doi:10.1007/s00406-019-01084-z
    1. Pham TH, Gardier AM. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacol Ther. 2019;199:58–90. doi:10.1016/j.pharmthera.2019.02.017
    1. Barrett W, Buxhoeveden M, Dhillon S. Ketamine: a versatile tool for anesthesia and analgesia. Curr Opin Anaesthesiol. 2020;33(5):633–638. doi:10.1097/ACO.0000000000000916
    1. Weiser TG, Haynes AB, Molina G, et al. Size and distribution of the global volume of surgery in 2012. Bull World Health Organ. 2016;94:201–9F. doi:10.2471/BLT.15.159293
    1. Ruis C, Wajer IH, Robe P, van Zandvoort M. Anxiety in the preoperative phase of awake brain tumor surgery. Clin Neurol Neurosurg. 2017;157:7–10. doi:10.1016/j.clineuro.2017.03.018
    1. Hellstadius Y, Lagergren J, Zylstra J, et al. Prevalence and predictors of anxiety and depression among esophageal cancer patients prior to surgery. Dis Esophagus. 2016;29:1128–1134. doi:10.1111/dote.12437
    1. Britteon P, Cullum N, Sutton M. Association between psychological health and wound complications after surgery. Br J Surg. 2017;104:769–776. doi:10.1002/bjs.10474
    1. Wichniak A, Wierzbicka A, Jernajczyk W. Sleep as a biomarker for depression. Int Rev Psychiatry. 2013;25(5):632–645. doi:10.3109/09540261.2013.812067
    1. Olbrich S, Arns M. EEG biomarkers in major depressive disorder: discriminative power and prediction of treatment response. Int Rev Psychiatry. 2013;25(5):604–618. doi:10.3109/09540261.2013.816269
    1. Ni P, Dong H, Zhou Q, et al. Preoperative Sleep Disturbance Exaggerates Surgery-Induced Neuroinflammation and Neuronal Damage in Aged Mice. Mediators Inflamm. 2019;2019:8301725. doi:10.1155/2019/8301725
    1. Pace‐Schott EF, Hobson JA. The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci. 2002;3(8):591–605. doi:10.1038/nrn895
    1. Wang YQ, Li R, Zhang MQ, Zhang Z, Qu WM, Huang ZL. The neurological mechanisms and treatments of REM sleep disturbances in depression. Curr Neuropharmacol. 2015;13(4):543–553. doi:10.2174/1570159X13666150310002540
    1. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. 2010;167(5):509–527. doi:10.1176/appi.ajp.2010.09101452
    1. Li JZ, Bunney BG, Meng F, et al. Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. Proc Natl Acad Sci USA. 2013;110(24):9950–9955. doi:10.1073/pnas.1305814110
    1. Lamont EW, Legault‐Coutu D, Cermakian N, Boivin DB. The role of circadian clock genes in mental disorders. Dialogues Clin Neurosci. 2007;9(3):333.
    1. Satyanarayanan SK, Su H, Lin YW, Su KP. Circadian Rhythm and Melatonin in the Treatment of Depression. Curr Pharm Des. 2018;24(22):2549–2555. doi:10.2174/1381612824666180803112304
    1. Li SX, Liu LJ, Xu LZ, et al. Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. Psychoneuroendocrinology. 2013;38(11):2789–2799. doi:10.1016/j.psyneuen.2013.07.009
    1. Patke A, Murphy PJ, Onat OE, et al. Mutation of the human circadian clock gene CRY1 in familial delayed sleep phase disorder. Cell. 2017;169(2):203–215.e13. doi:10.1016/j.cell.2017.03.027
    1. Krysta K, Krzystanek M, Bratek A, Krupka-Matuszczyk I. Sleep and inflammatory markers in different psychiatric disorders. J Neural Transm. 2017;124(Suppl 1):179–186. doi:10.1007/s00702-015-1492-3
    1. Jiang-Xie LF, Yin L, Zhao S, et al. A Common Neuroendocrine Substrate for Diverse General Anesthetics and Sleep. Neuron. 2019;102(5):1053–1065.e4. doi:10.1016/j.neuron.2019.03.033
    1. Luo M, Song B, Zhu J. Electroacupuncture: a New Approach for Improved Postoperative Sleep Quality After General Anesthesia. Nat Sci Sleep. 2020;12:583–592. doi:10.2147/NSS.S261043
    1. Ozone M, Itoh H, Yamadera W, et al. Changes in subjective sleepiness, subjective fatigue and nocturnal sleep after anaesthesia with propofol. Psychiatry Clin Neurosci. 2000;54:317–318. doi:10.1046/j.1440-1819.2000.00694.x
    1. Steinmetz J, Holm-Knudsen R, Eriksen K, Marxen D, Rasmussen LS. Quality differences in postoperative sleep between propofol-remifentanil and sevoflflurane anesthesia in infants. Anaesth Analg. 2007;104:779–783. doi:10.1213/01.ane.0000255694.00651.5b
    1. Dispersyn G, Touitou Y, Coste O, et al. Desynchronization of daily rest-activity rhythm in the days following light propofol anesthesia for colonoscopy. Clin Pharmacol Ther. 2009;85(1):51e5. doi:10.1038/clpt.2008.179
    1. Kincheski GC, Valentim IS, Clarke JR, et al. Chronic sleep restriction promotes brain inflammation and synapse loss, and potentiates memory impairment induced by amyloid-β oligomers in mice. Brain Behav Immun. 2017;64:140–151. doi:10.1016/j.bbi.2017.04.007
    1. Brosnan RJ, Thiesen R. Increased NMDA receptor inhibition at an increased Sevoflurane MAC. BMC Anesthesiol. 2012;12:12. doi:10.1186/1471-2253-12-12
    1. Hummer DL, Ehlen JC. Sustained activation of GABAA receptors in the suprachiasmatic nucleus mediates light-induced phase delays of the circadian clock: a novel function of ionotropic receptors. Eur J Neurosci. 2015;42(2):1830e8. doi:10.1111/ejn.12918
    1. Kadota K, Iijima N, Ohe-Hayashi Y, et al. Timedependent repression of mPer2 expression in the suprachiasmatic nucleus by inhalation anesthesia with sevoflflurane. Neurosci Lett. 2012;528(2):153e8. doi:10.1016/j.neulet.2012.07.061
    1. Anzai M, Iijima N, Higo S, et al. Direct and specific effect of sevoflurane anesthesia on rat Per2 expression in the suprachiasmatic nucleus. PLoS One. 2013;8(3):e59454. doi:10.1371/journal.pone.0059454
    1. Ohe Y, Iijima N, Kadota K, Sakamoto A, Ozawa H. The general anesthetic sevoflurane affects the expression of clock gene mPer2 accompanying the change of NAD(þ) level in the suprachiasmatic nucleus of mice. Neurosci Lett. 2011;490(3):231e6. doi:10.1016/j.neulet.2010.12.059
    1. Kobayashi K, Takemori K, Sakamoto A. Circadian gene expression is suppressed during sevoflurane anesthesia and the suppression persists after awakening. Brain Res. 2007;1185:1e7. doi:10.1016/j.brainres.2007.09.011
    1. Bellet MM, Vawter MP, Bunney BG, Bunney WE, Sassone-Corsi P. Ketamine influences CLOCK: BMAL1 function leading to altered circadian gene expression. PLoS One. 2011;6(8):e23982. doi:10.1371/journal.pone.0023982
    1. Doi M, Hirayama J, Sassone-Corsi P. Circadian regulator CLOCK is a histone acetyltransferase. Cell. 2006;125(3):497e508. doi:10.1016/j.cell.2006.03.033
    1. Wu CL, Raja SN. Treatment of acute postoperative pain. Lancet. 2011;377:2215e25. doi:10.1016/S0140-6736(11)60245-6
    1. Sommer M, de Rijke JM, van Kleef M, et al. The prevalence of postoperative pain in a sample of 1490 surgical inpatients. Eur J Anaesthesiol. 2008;25:267e74. doi:10.1017/S0265021507003031
    1. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367:1618e25. doi:10.1016/S0140-6736(06)68700-X
    1. Haack M, Simpson N, Sethna N, Kaur S, Mullington J. Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications. Neuropsychopharmacology. 2020;45(1):205–216. doi:10.1038/s41386-019-0439-z
    1. Perogamvros L, Schwartz S. The roles of the reward system in sleep and dreaming. Neurosci Biobehav Rev. 2012;36:1934–1951. doi:10.1016/j.neubiorev.2012.05.010
    1. Qiu MH, Liu W, Qu WM, Urade Y, Lu J, Huang ZL. The role of nucleus accumbens core/shell in sleep-wake regulation and their involvement in modafinil-induced arousal. PLoS One. 2012;7:e45471. doi:10.1371/journal.pone.0045471
    1. Foo H, Mason P. Brainstem modulation of pain during sleep and waking. Sleep Med Rev. 2003;7:145–154. doi:10.1053/smrv.2002.0224
    1. Julien N, Marchand S. Endogenous pain inhibitory systems activated by spatial summation are opioid-mediated. Neurosci Lett. 2006;401:256–260. doi:10.1016/j.neulet.2006.03.032
    1. Staud R, Robinson ME, Vierck CJ Jr, Price DD. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain. 2003;101:167–174. doi:10.1016/S0304-3959(02)00325-1
    1. Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. J Pain. 2013;14(12):1539–1552. doi:10.1016/j.jpain.2013.08.007
    1. Dugger BN, Dickson DW. Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017;9(7):a028035. doi:10.1101/cshperspect.a028035
    1. Malhotra RK. Neurodegenerative Disorders and Sleep. Sleep Med Clin. 2018;13(1):63–70. doi:10.1016/j.jsmc.2017.09.006
    1. Ju YS, Ooms SJ, Sutphen C, et al. Slow wave sleep disruption increases cerebrospinal fluid amyloid-beta levels. Brain. 2017;140:2104–2111. doi:10.1093/brain/awx148
    1. Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid beta-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014;71:971–977. doi:10.1001/jamaneurol.2014.1173
    1. Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005–1007. doi:10.1126/science.1180962
    1. Di MA, Joshi YB, Pratico D. Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer’s disease with plaques and tangles. Neurobiol Aging. 2014;35:1813–1820. doi:10.1016/j.neurobiolaging.2014.02.011
    1. Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson0 s disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1583–1590. doi:10.1002/mds.25945
    1. Braak H, Ghebremedhin E, Rub U, Bratzke H. and Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:121–134. doi:10.1007/s00441-004-0956-9
    1. Christensen JA, Nikolic M, Warby SC, et al. Sleep spindle alterations in patients with Parkinson’s disease. Front Hum Neurosci. 2015;9:233. doi:10.3389/fnhum.2015.00233
    1. Pont-Sunyer C, Iranzo A, Gaig C, et al. Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers. PLoS One. 2015;10:e0132368. doi:10.1371/journal.pone.0132368
    1. O’Dowd S, Galna B, Morris R, et al. Poor Sleep Quality and Progression of Gait Impairment in an Incident Parkinson’s Disease Cohort. J Parkinson’s Dis. 2017;7:465–470. doi:10.3233/JPD-161062
    1. Ma Y, Liang L, Zheng F, Shi L, Zhong B, Xie W. Association Between Sleep Duration and Cognitive Decline. JAMA Netw Open. 2020;3(9):e2013573. doi:10.1001/jamanetworkopen.2020.13573
    1. Liu Y, Wheaton AG, Chapman DP, Croft JB. Sleep duration and chronic diseases among US adults age 45 years and older: evidence from the 2010 behavioral risk factor surveillance system. Sleep. 2013;36:1421–1427. doi:10.5665/sleep.3028
    1. Tworoger SS, Lee S, Schernhammer ES, Grodstein F. The association of self-reported sleep duration, difficulty sleeping, and snoring with cognitive function in older women. Alzheimer Dis Assoc Disord. 2006;20:41–48. doi:10.1097/01.wad.0000201850.52707.80
    1. Tranah GJ, Blackwell T, Stone KL, et al. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol. 2011;70:722–732. doi:10.1002/ana.22468
    1. Diekelmann S, Born J. The memory function of sleep. Nat Rev Neurosci. 2010;11:114–126.
    1. Stickgold R. Sleep-dependent memory consolidation. Nature. 2005;437:1272–1278. doi:10.1038/nature04286
    1. Havekes R, Vecsey CG, Abel T. The impact of sleep deprivation on neuronal and glial signaling pathways important for memory and synaptic plasticity. Cell Signal. 2012;24:1251–1260. doi:10.1016/j.cellsig.2012.02.010
    1. Zhu B, Dong Y, Xu Z, et al. Sleep disturbance induces neuroinflammation and impairment of learning and memory. Neurobiol Dis. 2012;48:348–355. doi:10.1016/j.nbd.2012.06.022
    1. Meerlo P, Mistlberger RE, Jacobs BL, Craig Heller H, McGinty D. New neurons in the adult brain: the role of sleep and consequences of sleep loss. Sleep Med Rev. 2009;13:187–194. doi:10.1016/j.smrv.2008.07.004
    1. Nair D, Dayyat EA, Zhang SX, Wang Y, Gozal D. Intermittent hypoxia-induced cognitive deficits are mediated by NADPH oxidase activity in a murine model of sleep apnea. PLoS One. 2011;6:e19847. doi:10.1371/journal.pone.0019847
    1. Gao L, Tian S, Gao H, Xu Y. Hypoxia increases Aβ-induced tau phosphorylation by calpain and promotes behavioral consequences in AD transgenic mice. J Mol Neurosci. 2013;51:138–147. doi:10.1007/s12031-013-9966-y
    1. Li L, Zhang X, Yang D, Luo G, Chen S, Le W. Hypoxia increases Aβ generation by altering β- and γ-cleavage of APP. Neurobiol Aging. 2009;30:1091–1098. doi:10.1016/j.neurobiolaging.2007.10.011
    1. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol. 2004;25:177–195. doi:10.1016/j.yfrne.2004.08.001
    1. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: nature’s most versatile biological signal? FEBS J. 2006;273:2813–2838. doi:10.1111/j.1742-4658.2006.05322.x
    1. Golombek DA, Pevet P, Cardinali DP. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci Biobehav Rev. 1996;20:403–412. doi:10.1016/0149-7634(95)00052-6
    1. Mantovani M, Pertile R, Calixto JB, Santos AR, Rodrigues AL. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway. Neurosci Lett. 2003;343:1–4. doi:10.1016/S0304-3940(03)00306-9
    1. Mantovani M, Pértile R, Calixto JB, Santos AR, Rodrigues AL. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway. Neurosci Lett. 2003;343(1):1–4. doi:10.1016/s0304-3940(03)00306
    1. Sanacora G, Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets. 2007;6:127–140. doi:10.2174/187152707780363294
    1. Detanico BC, Piato AL, Freitas JJ, et al. Antidepressant-like effects of melatonin in the mouse chronic mild stress model. Eur J Pharmacol. 2009;607(1–3):121–125. doi:10.1016/j.ejphar.2009.02.037
    1. Raghavendra V, Kaur G, Kulkarni SK. Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation. Eur Neuropsychopharmacol. 2000;10:473–481. doi:10.1016/S0924-977X(00)00115-2
    1. Alghamdi BS. The neuroprotective role of melatonin in neurological disorders. J Neurosci Res. 2018;96(7):1136–1149. doi:10.1002/jnr.24220
    1. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res. 2005;38:145–152. doi:10.1002/jnr.24220
    1. Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type. Biol Psychiatry. 1999;45(12):1646–1652. doi:10.1016/S0006-3223(98)00255-8
    1. Wu YH, Feenstra MG, Zhou JN, et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab. 2003;88(12):5898–5906. doi:10.1210/jc.2003-030833
    1. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003;35(2):125–130. doi:10.1034/j.1600-079X.2003.00065.x
    1. Olcese JM, Cao C, Mori T, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res. 2009;47(1):82–96. doi:10.1111/j.1600-079X.2009.00692.x
    1. Rudnitskaya EA, Muraleva NA, Maksimova KY, Kiseleva E, Kolosova NG, Stefanova NA. Melatonin Attenuates Memory Impairment, Amyloid-beta Accumulation, and Neurodegeneration in a Rat Model of Sporadic Alzheimer’s Disease. J Alzheimer’s Dis. 2015;47(1):103–116. doi:10.3233/jad-150161
    1. Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31:335–343. doi:10.1002/da.22253
    1. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methylD-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71:1605–1611. doi:10.4088/JCP.09m05327blu
    1. Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76:970–976. doi:10.1016/j.biopsych.2014.03.026
    1. Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801–811. doi:10.1038/mp.2017.255
    1. Zanos P, Piantadosi SC, Wu HQ, et al. The prodrug 4- chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition. J Pharmacol Exp Ther. 2015;355:76–85. doi:10.1124/jpet.115.225664
    1. Zanos P, Thompson SM, Duman RS, Zarate CA, Gould TD. Gould TD Convergent mechanisms underlying rapid antidepressant action. CNS Drugs. 2018;32:197–227. doi:10.1007/s40263-018-0492-x
    1. Yang Y, Cui Y, Sang K, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554(7692):317–322. doi:10.1038/nature25509
    1. Matveychuk D, Thomas RK, Swainson J, et al. Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther Adv Psychopharmacol. 2020;10:2045125320916657. doi:10.1177/2045125320916657
    1. Aleksandrova LR, Phillips AG, Wang YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry-Neurosci. 2017;42(4):222–229. doi:10.1503/jpn.160175
    1. Duncan WC Jr, Slonena E, Hejazi NS, et al. Motor-activity markers of circadian timekeeping are related to ketamine’s rapid antidepressant properties. Biol Psychiatry. 2017;82(5):361–369. doi:10.1016/j.biopsych.2017.03.011
    1. Bjorkholm C, Monteggia LM. BDNF: a key transducer of antidepressant effects. Neuropharmacology. 2016;102:72–79. doi:10.1016/j.neuropharm.2015.10.034
    1. Kadriu B, Musazzi L, Henter ID, et al. Glu-tamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments. Int J Neuropsychopharmacol. 2019;22(2):119–135. doi:10.1093/ijnp/pyy094
    1. Zhang JC, Yao W, Hashimoto K. Brain-derived neurotrophic factor(BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol. 2016;14(7):721–731. doi:10.2174/1570159X14666160119094646
    1. Derkach VA, Oh MC, Guire ES, et al. mechanisms of AMPA receptors in synaptic plas-ticity. Nat Rev Neurosci. 2007;8(2):101–113. doi:10.1038/nrn2055
    1. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–964. doi:10.1126/science.1190287
    1. Ago Y, Tanabe W, Higuchi M, et al. (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism. Int J Neuropsychopharmacol. 2019;22(10):665–674. doi:10.1093/ijnp/pyz041
    1. Ardalan M, Wegener G, Rafati AH, Nyengaard JR. S-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression. Int J Neuropsychopharmacol. 2017;20(3):247–256. doi:10.1093/ijnp/pyw098
    1. Vadivelu N, Schermer E, Kodumudi V, Belani K, Urman R, Kaye A. Role of ketamine for analgesia in adults and children. J Anaesthesiol Clin Pharmacol. 2016;32:298–306. doi:10.4103/0970-9185.168149
    1. Nesher N, Ekstein MP, Paz Y, Marouani N, Chazan S, Weinbroum AA. Morphine with adjuvant ketamine vs higher dose of morphine alone for immediate postthoracotomy analgesia. Chest. 2009;136:245–252. doi:10.1378/chest.08-0246
    1. Bornemann-Cimenti H, Wejbora M, Michaeli K, Edler A, Sandner-Kiesling A. The effects of minimal-dose versus low-dose S-ketamine on opioid consumption, hyperalgesia, and postoperative delirium: a triple-blinded, randomized, active- and placebo-controlled clinical trial. Minerva Anestesiol. 2016;82:1069–1076.
    1. Thiruvenkatarajan V, Wood R, Watts R, et al. The intraoperative use of non-opioid adjuvant analgesic agents: a survey of anaesthetists in Australia and New Zealand. BMC Anesthesiol. 2019;19(2):152–153. doi:10.1186/s12871-019-0857-9
    1. Vyklicky V, Korinek M, Smejkalova T, et al. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res. 2014;63(Suppl 1):S191–203. doi:10.33549/physiolres.932678
    1. Fan W, Liu Q, Zhu X, et al. Regulatory effects of anesthetics on nitric oxide. Life Sci. 2016;151:76–85. doi:10.1016/j.lfs.2016.02.094
    1. Wang CQ, Ye Y, Chen F, et al. Posttraumatic administration of a sub-anesthetic dose of ketamine exerts neuroprotection via attenuating inflammation and autophagy. Neuroscience. 2017;343:30–33. doi:10.1016/j.neuroscience.2016.11.029
    1. Masllow GA, Lipinski WJ, Matlen LB, et al. Isoflurane anesthesia does not satisfy the homeostatic need for rapid eye movement sleep. Anesth Analg. 2010;110:1283.
    1. Feinberg I, Campbell IG. Ketamine administration during waking increases delta EEG intensity in rat sleep. Neuropsychopharmacology. 1993;9:41–48. doi:10.1038/npp.1993.41
    1. Ahnaou A, Huysmans H, Biermans R, Manyakov NV, Drinkenburg WHIM. Ketamine: differential neurophysiological dynamics in functional networks in the rat brain. Transl Psychiatry. 2017;7(9):e1237. doi:10.1038/tp.2017.198
    1. Duncan WC, Sarasso S, Ferrarelli F, et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol. 2013;16(2):301–311. doi:10.1017/S1461145712000545
    1. Faraguna U, Vyazovskiy VV, Nelson AB, Tononi G, Cirelli C. A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. J Neurosci. 2008;28(15):4088–4095. doi:10.1523/JNEUROSCI.5510-07.2008
    1. Bunney BG, Li JZ, Walsh DM, et al. Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder. Mol Psychiatry. 2015;20:48–55. doi:10.1038/mp.2014.138
    1. Paul KN, Fukuhara C, Karom M, et al. AMPA/kinase receptor antagonist DNQX blocks the acute increase of Per2 mRNA levels in most but not all areas of the SCN. Brain Res Mol Brain Res. 2005;139:129–136. doi:10.1016/j.molbrainres.2005.05.017
    1. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–964. doi:10.1126/science.1190287
    1. Cao R, Lee B, Cho HY, Saklayen S, Obrietan K. Photic regulation of the mTOR signaling pathway in the suprachiasmatic circadian clock. Mol Cell Neurosci. 2008;38:312–324. doi:10.1016/j.mcn.2008.03.005
    1. Cao R, Li A, Cho HY, Lee B, Obrietan K. Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock. J Neurosci. 2010;30:6302–6314. doi:10.1523/JNEUROSCI.5482-09.2010
    1. Maiese K, Chong ZZ, Shang YC, Wang S. mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med. 2013;19:51–60. doi:10.1016/j.molmed.2012.11.001
    1. Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology. 2013;38:2268–2277. doi:10.1038/npp.2013.128
    1. Orozco-Solis R, Montellier E, Aguilar-Arnal L, et al. A circadian genomic signature common to ketamine and sleep deprivation in the anterior cingulate cortex. Biol Psychiatry. 2017;82(5):351–360. doi:10.1016/j.biopsych.2017.02.1176
    1. Mendez-David I, Guilloux J-P, Papp M, et al. S 47445 Produces Antidepressant- and Anxiolytic-Like Effects through Neurogenesis Dependent and Independent Mechanisms. Front Pharmacol. 2017;8:462. doi:10.3389/fphar.2017.00462
    1. Kushikata T, Sawada M, Niwa H, et al. Ketamine and propofol have opposite effects on postanesthetic sleep architecture in rats: relevance to the endogenous sleep-wakefulness substances orexin and melanin-concentrating hormone. J Anesth. 2016;30(3):437–443. doi:10.1007/s00540-016-2161-x
    1. Fried EI, Nesse RM. Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. J Affect Disord. 2015;172:96–102. doi:10.1016/j.jad.2014.10.010
    1. Wang G, Cheng Y, Gong M, et al. Systematic correlation between spine plasticity and the anxiety/depression-like phenotype induced by corticosterone in mice. NeuroReport. 2013;24:682–687. doi:10.1097/WNR.0b013e32836384db
    1. Fraga DB, Camargo A, Olescowicz G, et al. Ketamine, but not fluoxetine, rapidly rescues corticosterone-induced impairments on glucocorticoid receptor and dendritic branching in the hippocampus of mice. Metab Brain Dis. 2021;36(8):2223–2233. doi:10.1007/s11011-021-00743-2
    1. Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632. doi:10.1038/tp.2015.136
    1. Kessler RC. The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J Clin Psychiatr. 2007;2:10–19.
    1. Goldberg DP, Wittchen HU, Zimmerman P, Pfifister H, Beesdo-Baum K. Anxious and non-anxious forms of major depression: familial, personality and symptom characteristics. Psychol Med. 2013;44:1223–1234. doi:10.1017/S0033291713001827
    1. Glue P, Medlicott NJ, Harland S, et al. Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017;31(10):1302–1305. doi:10.1177/0269881117705089
    1. Banov MD, Young JR, Dunn T, Szabo ST. Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. CNS Spectr. 2020;25(3):331–342. doi:10.1017/S1092852919001238
    1. Fraga DB, Olescowicz G, Moretti M, et al. Anxiolytic effects of ascorbic acid and ketamine in mice. J Psychiatr Res. 2018;100:16–23. doi:10.1016/j.jpsychires.2018.02.006
    1. Wu C, Wang Y, He Y, et al. Sub-anesthetic and anesthetic ketamine produce different long-lasting behavioral phenotypes (24 h posttreatment) via inducing different brain-derived neurotrophic factor (BDNF) expression level in the hippocampus. Neurobiol Learn Mem. 2019;167:107136. doi:10.1016/j.nlm.2019.107136
    1. Pitsikas N, Boultadakis A. Pre-training administration of anesthetic ketamine differentially affects rats’ spatial and non-spatial recognition memory. Neuropharmacology. 2009;57(1):1–7. doi:10.1016/j.neuropharm.2009.03.015
    1. Hayley A, Green M, Downey L, et al. Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine. Psychopharmacology. 2018;235:1273–1282. doi:10.1007/s00213-018-4842-7
    1. Perry EB Jr, Cramer JA, Cho HS, et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology. 2007;192:253–260. doi:10.1007/s00213-007-0706-2
    1. de Souza I, Meurer Y, Tavares PM, et al. Episodic-like memory impairment induced by sub-anaesthetic doses of ketamine. Behav Brain Res. 2019;359:165–171. doi:10.1016/j.bbr.2018.10.031
    1. Morrison RL, Fedgchin M, Singh J, et al. Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology. 2018;235:1107–1119. doi:10.1007/s00213-018-4828-5

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit